Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 10/20 | 0.65 |
| ▸ | CDK2 | P24941 | 9/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.65 |
| ▸ | CA2 | P00918 | 4/20 | 0.64 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 8/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CDK7 | P50613 | 2/20 | 0.41 |
| ▸ | CDK9 | P50750 | 2/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCNH | P51946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13897549 | 0.87 | CDK1 (0.70) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL13898381 | 0.85 | CDK1 (0.67) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL13897631 | 0.83 | CDK1 (0.65) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL4025895 | 0.82 | CDK1 (0.70) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL4022058 | 0.82 | CDK1 (0.77) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL3966386 | 0.81 | CA2 (0.71) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL3872095 | 0.81 | CDK2 (0.59) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL14498989 | 0.80 | CDK2 (0.64) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL4027058 | 0.80 | CDK1 (0.73) | CDK1CDK2CCNB1CCNE1CA2 | |
| SCHEMBL14355372 | 0.80 | CDK1 (0.73) | CDK1CDK2CCNB1CCNE1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | CDK1 237/4885CDK2 105/4885CCNB1 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.